1
Chi Huey Wong, Martin Hendrix, Phil Alper, E Scott Priestley: Nucleic acid binders having an hydroxyamine motif. The Scripps Research Institute, Donald G Lewis, September 19, 2000: US06120997 (16 worldwide citation)

The invention relates to the combination of hydroxyamines with nucleic acid binding motifs to generate molecules and libraries of molecules targeting specific nucleic acid sequences. In particular, a series of libraries are constructed which contain hydroxyamine functionalities that are attached to ...


2
Hong Liu, Phil Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li: Inhibitors of cathepsin S. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, June 10, 2008: US07384970 (1 worldwide citation)

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease stat ...


3
Thomas Marsilje, Wenshuo Lu, Phil Alper, Daniel Mutnick, Yun He: Compounds and Compositions as Tpo Mimetics. Irm, Genomics Institute Of The, Novartis Research Foundation, August 14, 2008: US20080194668-A1

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopeni ...


4
Hong Liu, Phil Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li: Inhibitors of cathepsin S. Irm, Townsend And Townsend And Crew, December 9, 2004: US20040248887-A1

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease stat ...